Edition:
United Kingdom

SINOPHARM GROUP CO LTD (1099.HK)

1099.HK on Hong Kong Stock

32.45HKD
18 Dec 2018
Change (% chg)

-- (--)
Prev Close
HK$32.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,442,614
52-wk High
HK$45.65
52-wk Low
HK$29.35

Summary

Name Age Since Current Position

Zhiming Li

55 2017 Executive Chairman of the Board and Deputy Secretary of Party Committee

Yong Liu

49 2017 President, Executive Director

Qiyu Chen

46 2014 Non-Executive Vice Chairman of the Board

Xiuchang Jiang

54 2013 Chief Financial Officer, Vice President

Jun Lu

60 2004 Vice President

Shuangjun Xu

50 2011 Non-executive Vice President

Qingming Yu

54 2018 Executive Director

Fang Yao

49 2017 Chief Supervisor

Wei Liu

2011 Joint Company Secretary

Jindong Deng

53 2007 Non-Executive Director

Ping Ma

62 2016 Non-Executive Director

Lulin She

62 2014 Non-Executive Director

Qunbin Wang

49 2003 Non-Executive Director

Deyong Wen

47 2017 Non-Executive Director

Yijian Wu

48 2018 Non-Executive Director

Ling Li

57 2012 Independent Non-Executive Director

Zheng Dong Liu

48 2014 Independent Non-Executive Director

Wee Seng Tan

63 2014 Independent Non-Executive Director

Tze Shan Yu

62 2014 Independent Non-Executive Director

Fumin Zhuo

67 2016 Independent Non-Executive Director

Biographies

Name Description

Zhiming Li

Mr. Li Zhiming is an Executive Chairman of the Board, Deputy Secretary of Party Committee of Sinopharm Group Co. Ltd. Mr. Li joined the Company in May 2010 as the vice President, and has served as the President from November 2013 to November 2017, and has served as executive Director since January 2014 and the Chairman and the secretary of Party Committee since March 2017. Mr. Li was the chief legal advisor, the secretary of disciplinary committee, chairman of labor union and the deputy secretary of the Party Committee of the Company from October 2012 to March 2017. He has more than 36 years of working experience, over 32 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Li graduated from the Xinjiang Commerce College with associate degree and a major in finance and accounting in July 1981, and graduated from the economic management discipline of the Urumqi Branch of Xi’an Military Academy with associate degree in July 1997. Mr. Li was qualified as a senior economist and a chief pharmacist. Mr. Li was the deputy director of finance department of Xinjiang New & Special Ethnic Drug Store, deputy general manager and chief accountant of Xinjiang Pharmaceutical Industry and Trade Company, deputy general manager and chief accountant of Xinjiang New & Special Ethnic Drug Corporation, and deputy director of the office of the preparatory and leading group of Xinjiang Pharmaceutical Administration Bureau steering the construction of the group entity from July 1985 to July 1996. Mr. Li was general manager, chairman of the board of directors, secretary of the Party Committee of Xinjiang New & Special Ethnic Drug Corporation, and the director, general manager, vice chairman, chairman, and secretary of the Party Committee of Xinjiang Pharmaceutical Group Company (currently known as Sinopharm Group Xinjiang New & Special Pharmaceutical Co., Ltd.) from July 1996 to February 2016. Mr. Li is currently the director of Sinopharm Industrial Investment Co.,

Yong Liu

Mr. Liu Yong serves as President, Executive Director of the Company. Mr. Liu joined the Group in January 2003, he has served as the Group’s president since November 2017 and executive director since December 2017. Mr. Liu has over 26 years of working experience, over 23 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Liu obtained a bachelor’s degree in science, majoring in business administration of pharmaceutical enterprises, from China Pharmaceutical University in July 1992, a master’s degree in business administration from Fudan University in January 2000 and a doctoral degree in social and administrative pharmacy from China Pharmaceutical University in June 2016. Mr. Liu is a chief pharmacist and a practicing pharmacist. Mr. Liu was employed at Shanghai Pharmaceutical Station from July 1992 to July 1999, and served as the deputy general manager at the marketing department of China National Pharmaceutical Group Shanghai Corporation and the deputy general manager of Shanghai Guoda Drug Chain Store Co., Ltd. from July 1999 to April 2003. Mr. Liu was the general manager and secretary of Party Committee of Sinopharm Holding Shenyang Co., Ltd. from April 2003 to November 2009. He served as vice president of the Company from January 2009 to November 2017, secretary to the Board of the Company from October 2016 to November 2017, and has served as chief legal advisor of the Company from January 2014 to December 2017. Mr. Liu is currently the director of Sinopharm Industrial Investment Co., Ltd. and Sinopharm Holding Guoda Drugstores Co., Ltd., and chairman of Sinopharm Lerentang Pharmaceutical Co., Ltd. and China National Accord Medicines Co., Ltd.

Qiyu Chen

Mr. Chen Qiyu is Non-Executive Vice Chairman of the Board of Sinopharm Group Co., Ltd., with effect from 22 September 2014. He joined the Company on 16 January 2003, and had served as the chief Supervisor until 31 May 2010. He has served as a non-executive Director since 31 May 2010 and has been the vice Chairman since November 2013. He has over 25 years of working experience. He obtained a bachelor’s degree in genetics from Fudan University in July 1993 and a master’s degree of business administration from China Europe International Business School in September 2005. Mr. Chen was previously the chief financial officer, the board secretary, general manager, president and vice chairman of the board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. from July 1998 to May 2010, and has been its director and chairman since May 2005 and June 2010, respectively. He has served as the vice president and co-president of Fosun International Limited since August 2010, and has served as its executive director since July 2015. He has served as the vice president and co-president of Shanghai Fosun High Technology (Group) Co., Ltd. since January 2011, and has served as its director since July 2015 and has served as its Chairman since November 2017. Mr. Chen has been a director of Tianjin Pharmaceuticals Group Co., Ltd., Zhejiang DIAN Diagnostics Co., Ltd., and Beijing Sanyuan Food Co., Ltd. since February 2009, May 2010 and September 2015, respectively. Mr. Chen served as the supervisor, director as well as the director and general manager of Sinopharm Industrial Investment Co., Ltd from July 2008 to March 2014 successively, and has served as the vice chairman of the same since March 2014 till now. Mr. Chen is currently also the member of Shanghai 12th Committee of the Chinese People’s Political Consultative Conference, the chairman of China Medical Pharmaceutical Material Association and Shanghai Biopharmaceutics Industry Association.

Xiuchang Jiang

Mr. Jiang Xiuchang is Chief Financial Officer, Vice President of Sinopharm Group Co., Ltd. He joined the Company in May 2010 as the chief financial officer, and has been the vice president of the Company since July 2013. He has over 31 years of working experience, over 20 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Jiang obtained a bachelor’s degree in financial accounting from Zhongnan University of Economics and Law in July 1986, and graduated from the class for advanced studies of postgraduate courses in corporate management from the School of International Business Management of University of International Business and Economics in January 2005. Mr. Jiang was qualified as a senior economist and senior accountant. Mr. Jiang served at China National Pharmaceutical Group Co., Ltd. from July 1986 to March 2002, and was the deputy head of the department of information, reform office, finance department and deputy manager of the department of pharmacy. He was deputy head, head and chief financial officer of the finance department of China National Medicines Corporation Ltd. from March 2002 to May 2010. Mr. Jiang is currently the chairman of Sinopharm Holding Jiangxi Co., Ltd., Sinopharm Holding Shanxi Co., Ltd., Sinopharm Holding Inner Mongolia Co., Ltd., Sinopharm Holding Tianjin Co., Ltd. and Sinopharm Group Shanxi Co., Ltd. and China National Medicines Corporation Ltd., and the director of China National Accord Medicines Co., Ltd., Sinopharm Group Finance Co., Ltd., and the director and general manager of Sinopharm Holding Hong Kong Co., Ltd., and the executive director of Beijing Sinopharm Tianyuan Real Estate & Property Management Co., Ltd.

Jun Lu

Mr. Lu Jun serves as Vice President of Sinopharm Group Co., Ltd. Mr. Lu joined the Group in January 2003, and has been a vice president of the Company since June 2004. He served as the assistant to the general manager of the Company, the general manager of medicine retail business department and the head of the investment department of the Company concurrently from April 2003 to June 2004. Mr. Lu has over 43 years of working experience, over 20 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Lu obtained an executive master’s degree in business administration in Antai College of Economics and Management of Shanghai Jiao Tong University in December 2009. Mr. Lu was qualified as a senior economist. Mr. Lu taught at the Second Military Medical University from March 1980 to August 1998, and was previously the general manager of Sinopharm Group Shanghai Likang Medicine Co., Ltd. and Sinopharm Holding Guoda Drug Stores Co., Ltd. from August 1998 to June 2008. Mr. Lu is currently the director of Sinopharm Group Shanxi Co., Ltd. and Sinopharm-CICC (Shanghai) Medical & Healthcare Investment Management Co., Ltd., and chairman of Sichuan Pharmaceutical Group Co., Ltd. of CNPGC, Sinopharm Holding Jiangsu Co., Ltd., Sinopharm Holding Wuxi Co., Ltd., Sinopharm Holding Anhui Co., Ltd., Sinopharm Holding Changzhou Co., Ltd., Sinopharm Holding Zhejiang Co., Ltd., Sinopharm Holding Wenzhou Co., Ltd., Sinopharm Group Chemical Reagent Co., Ltd., Sinopharm Lingyun Biopharmaceutical (Shanghai) Co., Ltd. and Sinopharm Holding Hutchison Whampoa Pharmaceutical (Shanghai) Co., Ltd.

Shuangjun Xu

Mr. Xu Shuangjun serves as Non-executive Vice President of Sinopharm Group Co. Ltd. He has been the non-executive vice president of the Company since March 2011. He has over 32 years of working experience, over 24 years of which is management experience in the pharmaceutical and healthcare products industry. He graduated from the School of Pharmacy of the Second Military Medical University in Shanghai and obtained a bachelor’s degree in medicine in 2001. He further obtained a master’s degree in business administration from the Macau University of Science and Technology in 2006 and has the qualifications of practicing pharmacist and chief pharmacist. Mr. Xu was employed at Shijiazhuang Lerentang from October 1987 to March 1999. He was manager of the operating branch and the deputy general manager of Shijiazhuang City Medicines and Herbs Co., Ltd. from March 1999 to August 2004, and was the chairman and general manager of Hebei Zhongrui Medicines Co., Ltd., the general manager and secretary of the Party Committee of Shijiazhuang Lerentang Pharmaceutical Co., Ltd., and the chairman and general manager of and secretary of the Party Committee of Lerentang Pharmaceutical Group Co., Ltd. from August 2004 to May 2011. Mr. Xu was the vice chairman and general manager, secretary of the Party Committee, and chairman of Sinopharm Lerentang Pharmaceutical Co., Ltd. from May 2011 to December 2015, and has been its vice chairman since December 2015.

Qingming Yu

Mr. Yu Qingming serves as Executive Director of the company. He has been working in the pharmaceutical industry for 31 years, with experience in the management of pharmaceuticals, health products and medical devices and holds the professional title of senior engineer. Mr. Yu graduated from Shanghai Medical Equipment College (now known as University of Shanghai for Science and Technology) in 1987, and graduated from the Central Party School majoring in Economic Management in 2001. From July 1987 to April 1990, Mr. Yu successively served as Secretary of Communist League Branch at Beijing Pharmaceutical Station of China National Pharmaceutical Group Co., Ltd., Secretary to the General Manager and Secretary to the Administrative Party Branch of China Medical Instrument Corporation. From April 1990 to February 1997, he served in the State Pharmaceutical Administration, serving as Deputy Director, Chief Director and Department Secretary of the General Office. From February 1997 to December 2009, he successively served as Deputy General Manager of the China Sales Department and Manager of the Corporate Management Department, Assistant to Chairman, Vice President and Executive President of Zhuhai United Laboratories Co., Ltd. and Executive President of Federal Pharmaceutical International Holdings Limited. Mr. Yu was the Director, General Manager and Party Secretary of China Medical Instrument Corporation from December 2009 to August 2010. Since August 2010, Mr. Yu has been in a senior management position of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd. Since November 2016, he served as Chairman and Party Secretary of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd.

Fang Yao

Mr. Yao Fang is a Chief Supervisor of Sinopharm Group Co., Ltd. has served as the Supervisor of the Company since 7 January 2011. Mr. Yao obtained a bachelor’s degree in economics from Fudan University in July 1989 and a master of business administration degree from The Chinese University of Hong Kong in December 1993. Between 1993 and 2009, Mr. Yao served as assistant general manager of the international business department of Shanghai Wanguo Securities Co., Ltd. (currently known as Shenwan Hongyuan Group Co., Ltd.), general manager of Shanghai Shang Shi Assets Operation and Management Co., Ltd. and Shang Shi Management (Shanghai) Co., Ltd., managing director of Shanghai Industrial Pharmaceutical Investment Co., Ltd. (delisted on 12 February 2010), the chairman of Shanghai Overseas Co., Ltd., non-executive director of Lianhua Supermarket Holdings Co., Ltd. (stock code 0980), and executive director of Shanghai Industrial Holding Limited (stock code: 0363) listed on the Hong Kong Stock Exchange. Mr. Yao has served as a non-executive director of Biosino Bio- Technology and Science Incorporation (stock code: 8247) listed on the Hong Kong Stock Exchange from 24 January 2011 to 13 March 2014. Mr. Yao joined Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since April 2010. He currently serves as the executive director and co-president of Shanghai Fosun Pharmaceutical (Group) Co., Ltd..

Wei Liu

Dr. Liu Wei serves as Joint Company Secretary of Sinopharm Group Co. Ltd., since August 24, 2011. He is currently the managing partner of China Group and the managing partner of Beijing Office of DLA Piper. Dr. Liu has PRC lawyer qualification and is a solicitor qualified to practice law in Hong Kong, England and Wales. Dr. Liu graduated from the Northwest University of China, the Chinese University of Political Science and Law, the University of Cambridge, with a bachelor in Chinese literature, a master degree in law, a PhD in Law in 1982, 1986 and 1996 respectively. He also completed his Postgraduate Certificate in Laws (PCLL) of the University of Hong Kong in 2000. Dr. Liu was the first student from the mainland of the PRC to obtain a PhD in law from the University of Cambridge after 1949. Dr. Liu worked for several local and state PRC governmental authorities. He is currently a member of the Shaanxi CPPCC. Dr. Liu is currently the managing partner of China Group of DLA Piper and the partner in charge of the PRC affairs and practice. In 1988, Dr. Liu, as one of the lawyers working in Hong Kong in the early stage, participated in related work of the Hong Kong Basic Law, and then he was retained by the Securities and Futures Commission of Hong Kong as a PRC affairs officer responsible for the policies and supervision of law of red chip shares, H-shares and B-shares, and was responsible for coordination with the China Securities Regulatory Commission, the Shenzhen Stock Exchange and the Shanghai Stock Exchange.

Jindong Deng

Mr. Deng Jindong is Non-Executive Director of Sinopharm Group Co., Ltd. He joined the Group on 30 August 2007, and has been a non-executive Director since then. He has over 30 years of working experience, over 25 years of which is financial management experience. Mr. Deng obtained a bachelor’s degree in economics from Hangzhou Electronics Industry Institution (currently known as Hangzhou Dianzi University) in July 1986 and a master’s degree in economics from Central Institute of Finance and Economics (currently known as Central University of Finance & Economics) in January 1991. He is a non-practicing PRC certified public accountant. Mr. Deng was previously the chief financial officer of Economic Information Network Data Co., Ltd., senior audit manager of Taikang Life Insurance Co., Ltd. and the head of the accounting department of CNPGC from April 2000 to October 2001, from October 2001 to October 2002 and from October 2002 to October 2004, respectively. Mr. Deng has been the chief accountant of CNPGC from October 2004 to May 2017, and has served as its vice general manager since May 2017. Mr. Deng was a director and chief financial officer, and a director of Sinopharm Industrial Investment Co., Ltd. from July 2008 to August 2015 and from August 2015 to January 2016, respectively, he has also been its chairman since January 2016.

Ping Ma

Mr. Ma Ping serves as Non-Executive Director of the Company, effective 18 October 2016. Mr. Ma joined the Group and has served as the nonexecutive Director of the Company since October 2016. Mr. Ma has over 35 years of working experience. Mr. Ma received a bachelor degree from chemistry department of Fudan University in 1982. Mr. Ma served as principal clerk, engineer, vice director and director of Ministry of Labor and Personnel, National Pharmaceutical Administration, State Planning Commission, respectively from February 1982 to March 1992. He served as department manager, project manager, general manager of London Export Corporation, Hoechst (China), Lotus Healthcare, respectively from March 1992 to April 1994. He co-founded and served as managing director of BMP from April 1994 to October 1996. He served as investment director, business development director of Sinogen International Ltd. from October 1996 to May 1998. He served as vice president, COO, China general manager of United Medical Industrial Group from May 1998 to March 2000. He served as director, vice general manager of Tonghua Golden-horse Group (a Shenzhen Stock Exchange-listed company, stock code: 000766) from March 2000 to September 2001. He served as director, general manager of BMP (a Nasdaqlisted company, stock code: BJGP) from September 2001 to December 2005. He served as director, general manager of BioPro Pharmaceutical Inc. from December 2005 to December 2011. He has been serving as director of BioPro Pharmaceutical Inc. and project consultant of Principle Capital since December 2011, and has been serving as an external director of CNPGC since May 2016.

Lulin She

Mr. She Lulin is Non-Executive Director of Sinopharm Group Co., Ltd., with effect from 22 September 2014. He joined the Group as a non-executive Director on 16 January 2003. He was the vice Chairman and has served as the Chairman of from August 2007 to November 2013. He has around 34 years of working experience, over 31 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. She obtained a bachelor’s degree in science, majoring in Pharmacy, from Nanjing Pharmaceutical Institution (currently known as China Pharmaceutical University) in July 1982 and a master’s degree in business administration for executives from Tsinghua University in July 2005. Mr. She was previously the deputy head of the office, assistant to the general manager, deputy general manager and general manager of China National Pharmaceutical Group Guangzhou Corporation from August 1982 to August 1996. Mr. She was also the vice chairman of the board of directors and general manager of CNPGC from December 1998 to October 2004. Mr. She was a director, general manager and the secretary of Party Committee of CNPGC from October 2004 to October 2009. He was the vice chairman of the board of directors, general manager and deputy secretary of Party Committee of CNPGC since October 2009. Mr. She has been the chairman of the board of directors and legal representative of Sinopharm Industrial Investment Co., Ltd. from July 2008 to November 2013. Mr. She was the chairman of the board of directors of China National Medicines Corporation Ltd. from December 1998 to January 2001.

Qunbin Wang

Mr. Wang Qunbin is Non-Executive Director of Sinopharm Group Co., Ltd. He joined the Group on 16 January 2003, and has been a non-executive Director since then. He has around 26 years of working experience, over 23 years of which is management experience in biological medicine. Mr. Wang obtained a bachelor’s degree in science, majoring in genetics, from Fudan University in July 1991. Mr. Wang was previously a lecturer at the Genetic Research Institute of Fudan University from September 1991 to September 1993, and then a director and the general manager of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. from 1995 to October 2007 and a director of Tianjin Pharmaceutical Holdings Ltd. from March 2001 to February 2009. Mr. Wang has served as a director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since October 2007, and was its chairman of the board of directors from October 2007 to June 2010. Mr. Wang was a director of Shanghai Fosun High Technology (Group) Co., Ltd. from November 1994 to November 2017. He has been an executive director of Fosun International Limited (a company listed on the Hong Kong Stock Exchange) since August 2005, he served as the president of Fosun International Limited from January 2009 to March 2017 and served as the Chief Executive Officer of the same since March 2017. Mr. Wang has been a director of Henan Lingrui Pharmaceutical Company Ltd. (a company listed on the Shanghai Stock Exchange) from May 2002 to June 2017, and was also a director of Sinopharm Industrial Investment Co., Ltd. from July 2008 to March 2014

Deyong Wen

Mr. Wen Deyong is Non-Executive Director of the Company., 20 September 2017. Mr. Wen joined the Group and has served as the nonexecutive Director of the Company since September 2017. Mr. Wen graduated from Donghua University and received a master degree in business administration. Mr. Wen is currently the executive vice president of Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. and vice president of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. During the period from September 1995 to May 2016, Mr. Wen has served as the technician in water needle shop of Chongqing Pharmaceutical Co., Ltd. 6th Factory, the sales outworker in sales department, the sales director in sales company, the general manager in 2nd marketing department of Chongqing Yaoyou Pharmaceutical Co., Ltd., the general manager of northern unit of Chongqing Haisiman Company, the vice president and president of Chongqing Yaoyou Pharmaceutical Co., Ltd.

Yijian Wu

Mr. Wu Yijian is Non-Executive Director of the Company. Mr. Wu the president assistant and the director of the commercial pharmaceutical management committee of Shanghai Fosun Pharmaceutical Group Co., Ltd.. Mr. Wu has been with San-jiu Group since July 1993 and successively served as sales director of San-jiu Pharmaceutical trade Co., Ltd, the chief operating officer of San-jiu Pharmaceutical Chain Co., Ltd. and the deputy general manager of Shanghai San-jiu Pharmaceutical Technology Development Co., Ltd.. Mr. Wu has been with Fosun Pharmaceutical Group since June 2004 and successively served as the general manager of Shanghai Fosun Pharmaceutical investment Co., Ltd., Shanghai Fosun Pharmaceutical Co., Ltd. and Shanghai Fumei Pharmacy Co., Ltd.. In 2014, Mr. Wu was appointed as the vice president of Shanghai Yuyuan Tourist Mart Co., Ltd.. Mr. Wu graduated from Shanghai Medical University with a medical bachelor's degree in July 1993, successively obtained a master’s degree in business administration from Tsinghua university in July 2003, a master’s degree in accounting for senior accountant from The Chinese university of Hong Kong in November 2014, and completed the courses for the general manager in the China Europe International Business School of Management in July 2007.

Ling Li

Ms. Li Ling is an Independent Non-Executive Director of Sinopharm Group Co. Ltd. Ms. Li joined the Group on 29 December 2012, and has been an independent not-executive Director since then. Ms. Li has around 35 years of working experience. She obtained a bachelor’s degree in physics in August 1982 and a master’s degree in economics in February 1987 from Wuhan University, and obtained a master’s degree and a doctorate degree in economics from University of Pittsburgh in U.S.A in September 1990 and May 1994, respectively. Ms. Li worked at the Department of Economics of Towson University in Maryland, U.S.A as an associate professor with tenure from August 2000 to August 2003, and also taught at the Department of Economics of University of Pittsburgh in U.S.A and the Department of Management and Marketing of The Hong Kong Polytechnic University. Ms. Li has been an economics professor and Ph.D. supervisor at Research Institute of National Development, a director of Research Center of China Healthy Development of Peking University since June 2008, and is an expert who enjoys the special allowance of the State Council and is one of the “Top Ten Teachers” of Peking University. Ms. Li has served as an independent director of PICC Health Insurance Company Limited since 2009. Ms. Li currently also serves as the vice chairman of China Health Economics Association, a member of the State Council Health Reform Advisory Commission, a member of National Health and Family Planning Commission on public policy, an evaluation expert in the Pilot Project of Urban Resident Basic Medical Insurance implemented by the State Council, an advisor to the Beijing Municipal Government, an advisor to the pharmaceutical and healthcare reform of Guangdong Province and the vice chairman of Gerontological Society of China.

Zheng Dong Liu

Mr. Liu Zheng Dong is an Independent Non-Executive Director of the company since 21 September 2014. has been an independent non-executive Director of the Company since 21 September 2014. He is a lawyer who has more than 24 years of working experience as a practicing lawyer. Mr. Liu graduated from East China University of Political Science and Law (formerly known as East China School of Political Science and Law) with a bachelor’s degree in Law in 1991, and juris master’s degree in 2002. He served as an assistant prosecutor in Railway Transportation branch of Shanghai People’s Procuratorate from July 1991 to June 1994. From June 1994 to October 1998, Mr. Liu worked at Shanghai Hongqiao Law Firm as a lawyer. From October 1998, Mr. Liu co-founded Shanghai Junyue Law Firm with others as a senior partner and has been serving as head of the firm and a lawyer. Mr. Liu served as president of the Eighth Session of Shanghai Bar Association and was also honored as National Excellent Lawyer, Shanghai Excellent Non-litigation Lawyer and Shanghai Leading Talent. Currently, Mr. Liu currently serves as deputy to the Shanghai 15th People’s Congress, standing director of the National Lawyers Association, vice chairman of Shanghai Youth Federation, vice president of Shanghai General Chamber of Commerce, standing member of Shanghai Association of Industry and Commerce, etc. Mr. Liu also serves as arbitrators of China International Economic and Trade Arbitration Commission (CIETA), Shanghai International economic and Trade Arbitration Commission (SHIAC) and Shanghai Arbitration Commission (SAC), adjunct professor of East China University of Political Science and Law, parttime master tutor of the School of Law of Shanghai Jiao Tong University, visiting professor of each of Shanghai University of Political Science and Law and Lawyer School of Renmin University of China.

Wee Seng Tan

Mr. Tan Wee Seng is an Independent Non-Executive Director of the company. He has served as a non-executive Director since 21 September 2014 and has more than 40 years of working experience. Mr. Tan is a Chartered Global Management Accountant, Fellow member of the Chartered Institute of Management Accountants in United Kingdom, and the Hong Kong Institute of Directors. Mr. Tan has been with Reuters Group from April 1984 to June 2002. Mr. Tan served as executive director, chief finance officer and company secretary of Li Ning Company Limited (a company listed on the Hong Kong Stock Exchange), from January 2003 to November 2008. Mr Tan was an independent director and chairman of the audit committee of 7 Days Holdings Limited (whose shares were listed on the New York Stock Exchange between November 2009 to July 2013) until it was privatized. He was the Chairman of the Special Committee for Privatization of 7 Days Holdings Limited from October 2012 to July 2013. Mr. Tan currently also serves as independent non-executive director of each of Biostime International Holdings Limited (a company listed on the Hong Kong Stock Exchange), Sa Sa International Holdings Limited (a company listed on the Hong Kong Stock Exchange), CIFI Holdings (Group) Company Limited (a company listed on the Hong Kong Stock Exchange), Xtep International Holdings Limited (a company listed on the Hong Kong Stock Exchange), he is also an independent director of ReneSola Ltd. (a company listed on the New York Stock Exchange) and a director and chairman of finance and operation committee of Beijing City International School.

Tze Shan Yu

Mr. Yu Tze Shan Hailson is an Independent Non-Executive Director of the company. has served as a non-executive Director since 21 September 2014 and has more than 39 years of working experience. Mr. Yu graduated from the University of Calgary with a bachelor degree in Electrical Engineering in 1979, graduated from the University of Hong Kong with a master degree in Electrical Engineering in 1987, graduated from City University of Hong Kong with a master degree of law in Arbitration and Dispute Resolution in 1995 and completed the postgraduate diploma in Investment Management and post-graduate certificates in Hong Kong Laws and Traditional Chinese Medicine courses. Mr. Yu served as equipment maintenance and testing engineer, equipment maintenance and testing laboratory manager, computer engineering and system engineering manager of Ampex Ferrotec Limited (Hong Kong) successively from June 1979 to September 1987. Mr. Yu joined China International Trust and Investment Corporation Hong Kong (Holdings) Limited and served as the general manager of engineering research and development department, and consultant for Petroleum Development and LPG Tank Terminal Port successively from October 1987 to January 1998. Mr. Yu has been serving as the deputy managing director of Versitech Limited and deputy director of Technology Transfer Office of the University of Hong Kong since February 1998 till now. Mr Yu has been serving as an independent nonexecutive director of China Traditional Chinese Medicine Co., Ltd. (formerly known as Winteam Pharmaceutical Group Limited, a company listed on the Hong Kong Stock Exchange) since November 2013. He has served as an independent non-executive director of China NT Pharma Group Company Limited since June 2017 till now. Mr. Yu currently is a Charted Engineer, fellow of each of the Institute of Electrical Engineers, Hong Kong Institution of Engineers, the Chartered Institute of Arbitrators and Hong Kong Institute of Arbitrators.

Fumin Zhuo

Mr. Zhuo Fumin serves as Independent Non-Executive Director of the Company. Mr. Zhuo has been an independent nonexecutive Director since March 2016. Mr. Zhuo has more than 42 years of experience in the field of enterprise management and capital markets. Mr. Zhuo graduated from Shanghai Jiaotong University of Engineering Science in 1983. He subsequently obtained a master’s degree in economics from Fudan University in 1997. Mr. Zhuo currently serves as chairman and managing partner of V Star Capital. Between 1987 and 1995, Mr. Zhuo served senior positions including an office head and an officer assistant of the Shanghai Economic System Reform Committee. Between 1995 and 2002, Mr. Zhuo held in turn various senior positions at Shanghai Industrial Investment (Holdings) Co., Ltd., including the managing director and chief executive officer of Shanghai Industrial Holdings Limited (a company listed on the Hong Kong Stock Exchange, stock code: 363) and the chairman of SIIC Medical Science and Technology (Group) Limited. Mr. Zhuo has served as the chairman and the chief executive officer of Vertex China Investment Co., Ltd. (a wholly owned subsidiary of Vertex Management Group, a global venture capital management company), founder and chairman of Shanghai Kexing Investment Co., Ltd. and managing partner of GGV Capital, a venture capital fund since 2002. Mr. Zhuo is also an independent director of China Enterprise Company Limited (a company listed on the Shanghai Stock Exchange, stock code: 600675), Arcplus Group Plc (a company listed on the Shanghai Stock Exchange, stock code: 600629) and Daqo New Energy Corp. (a company listed on the New York Stock Exchange, stock code: DQ), Focus Media (a company listed on the Shenzhen Stock Exchange, stock code: 002027) and Shanghai Shine-Link International Logistics Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 603648), a non-executive Director of Besunyen Holdings Company Limited (a company listed on the Hong Kong Stock Exchange, stock

Basic Compensation